Osseon Therapeutics, Inc. has named Ron Clough as its new chief operative officer. Most recently Clough was vice-president of operations at Theken Spine and was a key executive in the acquisition and integration of Theken Spine into Integra LifeSciences, an international medical device company. Integra LifeSciences acquired Theken for $200 million dollars in a two-year earn out in July 2008.
Ron Clough to Head Operations at Osseon Therapeutics
1 min read Premium comments
Clough has spent years as an executive in the medical device industry, integrating all aspects of manufacturing, distribution, and regulatory affairs. “Osseon is very excited that Mr. Clough has joined the Management Team. He brings unparalleled experience and expertise in the spinal device market, ” said John Stalcup, Ph.D., Osseon president, in an August 29 press release.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. The firm is headquartered in Santa Rosa, California. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.